Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases

Matthew Ramotar, Sierra Barnes, Fabio Moraes, Archya Dasgupta, Normand Laperriere, Barbara-Ann Millar, Alejandro Berlin, Tatiana Conrad, Monique van Prooijen, Andrei Damyanovich, Robert Heaton, Young-Bin Cho, Catherine Coolens, Geoffrey Liu, Frances A Shepherd, Penelope Bradbury, Natasha Leighl, Mark Bernstein, Gelareh Zadeh, Paul Kongkham, Mark Doherty, David B Shultz, Matthew Ramotar, Sierra Barnes, Fabio Moraes, Archya Dasgupta, Normand Laperriere, Barbara-Ann Millar, Alejandro Berlin, Tatiana Conrad, Monique van Prooijen, Andrei Damyanovich, Robert Heaton, Young-Bin Cho, Catherine Coolens, Geoffrey Liu, Frances A Shepherd, Penelope Bradbury, Natasha Leighl, Mark Bernstein, Gelareh Zadeh, Paul Kongkham, Mark Doherty, David B Shultz

Abstract

Purpose: Brain metastases (BrM) are common in patients with epidermal growth factor receptor (EGFRm) mutant non-small cell lung cancer (NSCLC). We sought to determine the rate of neurologic death (ND) in this population.

Methods and materials: We analyzed data from 198 patients who received a diagnosis of BrM from EGFRm NSCLC between 2004 and 2016, comparing patients whose initial treatment for BrM was stereotactic radiosurgery with or without tyrosine kinase inhibitors (TKI), whole brain radiation therapy (WBRT) with or without TKI, or TKI alone. The incidence of ND was determined using a competing risks analysis. Univariate and multivariate analyses were used to identify clinical variables associated with this outcome.

Results: The percentage of patients who initially received stereotactic radiosurgery, whole brain radiation therapy, or TKI alone was 22%, 61%, and 17%, respectively. Median overall survival in these subgroups was 31.1, 14.6, and 24.6 months, respectively (P = .0016). The 5-year incidence of ND among all patients was 40% and did not significantly vary according to treatment group. In a multivariable model, only leptomeningeal disease at any point in a patient's disease course significantly correlated with ND (hazard ratio 4.75, P <.001).

Conclusions: Among our cohort of patients with BrM from EGFRm NSCLC, the incidence of ND was significantly higher than suggested by previous reports. BrM should be considered a driver of mortality in many patients with EGFRm NSCLC, and treatments providing better control of BrM, lower neurocognitive side effects, and maintenance of quality of life are needed.

© 2019 The Author(s).

Figures

Figure 1
Figure 1
Cumulative incidence of neurologic death in patients with epidermal growth factor-mutant non-small cell lung cancer who received a diagnosis of brain metastases or leptomeningeal disease, stratified by initial treatment. Abbreviations: SRS = stereotactic radiosurgery; TKI = tyrosine kinase inhibitor alone; WBRT = whole brain radiation therapy.
Figure 2
Figure 2
Overall survival of patients with epidermal growth factor-mutant non-small cell lung cancer diagnosed with brain metastases or leptomeningeal disease according to initial treatment. Abbreviations: SRS = stereotactic radiosurgery; TKI = tyrosine kinase inhibitor alone; WBRT = whole brain radiation therapy.
Figure 3
Figure 3
Cumulative incidence of intracranial progression after initial treatment for patients with epidermal growth factor-mutant non-small cell lung cancer who received a diagnosis of brain metastases or leptomeningeal disease. Abbreviations: SRS = stereotactic radiosurgery; TKI = tyrosine kinase inhibitor alone; WBRT = whole brain radiation therapy.

References

    1. Hendriks L.E.L., Smit E.F., Vosse B.A.H. EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? Lung Cancer. 2014;84:86–91.
    1. Rangachari D., Yamaguchi N., VanderLaan P.A. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88:108–111.
    1. Han G., Bi J., Tan W. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: Is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget. 2016;7:56998–57010.
    1. Brown P.D., Jaeckle K., Ballman K.V. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA. 2016;316:401–409.
    1. Roberge D., Chan M. Stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for 5-15 brain metastases.
    1. Yamamoto M., Serizawa T., Shuto T. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol. 2014;15:387–395.
    1. Shaw E., Scott C., Souhami L. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291–298.
    1. Bates A., Gonzalez-Viana E., Cruickshank G., Roques T. Primary and metastatic brain tumours in adults: Summary of NICE guidance. 2018;362:k2924.
    1. Park S.J., Kim H.T., Lee D.H. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77:556–560.
    1. Luo S., Chen L., Chen X., Xie X. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget. 2015;6:16725–16734.
    1. Gui Q., Liu J., Li D., Xu C. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs. World J Surg Oncol. 2017;15:184.
    1. Magnuson W.J., Lester-Coll N.H., Wu A.J. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis. J Clin Oncol. 2017;35:1070–1077.
    1. Doherty M.K., Korpanty G.J., Tomasini P. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol. 2017;123:195–202.
    1. Jiang T., Su C., Li X. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol. 2016;11:1718–1728.
    1. Miyawaki E., Kenmotsu H., Mori K. Optimal sequence of local and EGFR-TKI therapy for EGFR-mutant non-small cell lung cancer with brain metastases stratified by number of brain metastases. Int J Radiat Oncol Biol Phys. 2019;104:604–613.
    1. Sperduto P.W., Yang T.J., Beal K. The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys. 2016;96:406–413.
    1. Robin T.P., Camidge D.R., Stuhr K. Excellent outcomes with radiosurgery for multiple brain metastases in ALK and EGFR driven non-small cell lung cancer. J Thorac Oncol. 2018;13:715–720.
    1. Ammirati M., Nahed B.V., Andrews D., Chen C.C., Olson J.J. Congress of Neurologic Surgeons systematic review and evidence-based guidelines on treatment options for adults with multiple metastatic brain tumors. Neurosurgery. 2019;84:E180–E182.
    1. Kocher M., Soffietti R., Abacioglu U. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–141.
    1. Patchell R.A., Tibbs P.A., Regine W.F. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 1998;280:1485–1489.
    1. Sperduto P.W., Yang T.J., Beal K. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA) JAMA Oncol. 2017;3:827–831.
    1. Li Y.S., Jiang B.Y., Yang J.J. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol. 2016;11:1962–1969.
    1. Ahn M.J., Kim D.W., Cho B.C. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): A phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5:891–902.
    1. How J., Mann J., Laczniak A.N., Baggstrom M.Q. Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: Review of the literature. Clin Lung Cancer. 2017;18:354–363.
    1. Liao B.C., Lee J.H., Lin C.C. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol. 2015;10:1754–1761.
    1. Sung S., Lee S.W., Kwak Y.K., Kang J.H., Hong S.H., Kim Y.S. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer. J Neurooncol. Aug. 2018;139:205–213.
    1. Reungwetwattana T., Nakagawa K., Cho B.C. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung. Cancer. 2018;36:3290–3297.
    1. Gondi V., Deshmukh S., Brown P.D. NRG oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM) J Clin Oncol. 2019;37(15 suppl) 2009-2009.
    1. Study of osimertinib + SRS vs osimertinib alone for brain metastases in EGFR positive patients with NSCLC.
    1. A randomised phase II trial of osimertinib with or without SRS for EGFR mutated NSCLC with brain metastases.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever